.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AX05_Pirfenidone.Pirfenidone .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AX05_Pirfenidone.Pirfenidone| name: | Pirfenidone |
| ATC code: | L04AX05 | route: | oral |
| n-compartments | 1 |
Pirfenidone is an orally administered antifibrotic agent used for the treatment of idiopathic pulmonary fibrosis (IPF). It exhibits antifibrotic, anti-inflammatory, and antioxidant properties. Pirfenidone is approved for clinical use in the treatment of IPF in multiple countries including the US, EU, and Japan.
Pharmacokinetic parameters in healthy adult subjects (male and female, aged 18–55 years) after single-dose administration.
Rastegar-Pouyani, N, et al., & Sahebkar, A (2024). Targeting cancer-associated fibroblasts with pirfenidone: A novel approach for cancer therapy. Tissue & cell 91 102624–None. DOI:10.1016/j.tice.2024.102624 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39581071